Chemistry:25T7-NBOMe
From HandWiki
25T7-NBOMe, also known as 2C-T-7-NBOMe or NBOMe-2C-T-7 as well as N-(2-methoxybenzyl)-4-propylthio-2,5-dimethoxyphenethylamine, is a serotonergic psychedelic of the 25-NB (NBOMe) family. It is the NBOMe analogue of 2C-T-7. The compound has been sold as a designer drug.[1][2][3][4][5]
Use and effects
The active dose range and route of 25T7-NBOMe do not appear to have been described.[6]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 1,800 |
| 5-HT1B | 1,902 |
| 5-HT1D | 2,176 |
| 5-HT1E | ND |
| 5-HT1F | ND |
| 5-HT2A | 0.68–1.1 (Ki) 7.42–260 (EC50) 41–173% (Emax) |
| 5-HT2B | 2.3 (Ki) 310 (EC50) 14% (Emax) |
| 5-HT2C | 6.4 (Ki) 19.1 (EC50) 95% (Emax) |
| 5-HT3 | ND |
| 5-HT4 | ND |
| 5-HT5A | ND |
| 5-HT6 | 68.8 |
| 5-HT7 | ND |
| α1A | 340 |
| α1B, α1D | ND |
| α2A | 360 |
| α2B, α2C | ND |
| β1–β3 | ND |
| D1 | 4,100 |
| D2 | 1,000 |
| D3 | 1,400 |
| D4, D5 | ND |
| H1 | 1,200 |
| H2–H4 | ND |
| M1–M5 | ND |
| I1 | ND |
| σ1, σ2 | ND |
| ORs | ND |
| TAAR1 | 1,000 (Ki) (mouse) 88–90 (Ki) (rat) 2,100 (EC50) (mouse) 550 (EC50) (rat) >10,000 (EC50) (human) 68% (Emax) (mouse) 52% (Emax) (rat) |
| SERT | 3,200 (Ki) 17,000 (IC50) ND (EC50) |
| NET | 3,700 (Ki) 34,000 (IC50) ND (EC50) |
| DAT | 4,800 (Ki) 55,000 (IC50) ND (EC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [7][8][9][1][2][10] | |
25T7-NBOMe acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[1] Its affinities and activities at a variety of other receptors and transporters have also been described.[1]
History
25T7-NBOMe was first described in the scientific literature by 2012.[11]
Society and culture
Legal status
Canada
25T7-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.[12]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology 99: 546–553. December 2015. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099. https://psilosybiini.info/paperit/Receptor%20interaction%20profiles%20of%20novel%20N-2-methoxybenzyl%20(NBOMe)%20derivatives%20of%202,5-dimethoxy-substituted%20phenethylamines%20(2C%20drugs)%20(Rickli%20et%20al.,%202015).pdf.
- ↑ 2.0 2.1 "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chemical Neuroscience 14 (15): 2727–2742. August 2023. doi:10.1021/acschemneuro.3c00267. PMID 37474114.
- ↑ "The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography". Forensic Science International 267: 89–95. October 2016. doi:10.1016/j.forsciint.2016.08.008. PMID 27572638.
- ↑ "Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry". Drug Testing and Analysis 10 (7): 1184–1191. February 2018. doi:10.1002/dta.2371. PMID 29455470.
- ↑ "Simultaneous LC-MS/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine". Forensic Science International 325. August 2021. doi:10.1016/j.forsciint.2021.110884. PMID 34245937.
- ↑ "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol 21 (10): 926–931. October 2018. doi:10.1093/ijnp/pyy047. PMID 29850881.
- ↑ "Ki values for 25T7-NBOMe". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill. 15 July 2025. https://pdspdb.unc.edu/kidb2/kidb/web/kis-results/index?KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=14688&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D=&KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=14689&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D=.
- ↑ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
- ↑ "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience 5 (3): 243–249. March 2014. doi:10.1021/cn400216u. PMID 24397362.
- ↑ "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther 357 (1): 134–144. April 2016. doi:10.1124/jpet.115.229765. PMID 26791601. https://d1wqtxts1xzle7.cloudfront.net/74120533/eae6c6e62565b82d46b4d111bbea0f77b9c2-libre.pdf?1635931703=&response-content-disposition=inline%3B+filename%3DIn_Vitro_Characterization_of_Psychoactiv.pdf&Expires=1746838268&Signature=Sy4fJ90yUhxs68314NxYsW5PAaNrBGePRu35WRR4PIF-3YC7Z~sLdnCn5wfqqbLg9bDEGdt~oW55ugMP3D3jgA0BoRI~~GOb0NQOwrtfUEQK1PQs1uuN9qg5Y1ct8z5NsABm44RgtukkwRMdU6fO7OlfIsQ68hOiFk129Ll7UYqldxD2f1xhE2fTTfsxSpb8cMCJzHn7-ItqLdwnAUPFK7WggDIjmY1kCnaHLwIxMwdJCAq8L6DYzSTg7pZkbR8qlou~GXbTPQt~gYpyZTJp5hgW-7V6K5wLlQ7Z2xE7B0f9wEfuc1W1QNafg125Tr-vvAe4LEGKXV58bnn1bpfWKw__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA.
- ↑ "Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I.". Microgram Journal 9 (2): 84–109. 2012. https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_84-109.pdf.
- ↑ "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html.
External links
 |  |
